Abstract
Background Extended-spectrum betalactamase (ESBL-) producing K. pneumoniae is one of the most common causes of infections with antimicrobial resistant bacteria worldwide. The spread of colonization of humans with this pathogen is on the rise. The future prevalence of colonization with ESBL-producing K. pneumoniae, and the potential of public health interventions to lower it, remain uncertain.
Methods Based on detailed data on antimicrobial consumption and susceptibility systematically recorded for over 13 years in a Swiss region, we developed a mathematical model to i) reconstruct the observed course of colonization with ESBL-producing K. pneumoniae; and ii) to assess the potential impact of public health interventions on future trends in colonization.
Results Simulated prevalence of colonization with ESBL-producing K. pneumoniae stabilized in the near future when rates of antimicrobial consumption and in-hospital transmission remained stable in the main analyses (simulated prevalence in 2025 was 5.3% (5.0%-9.1%) in hospitals and 2.7% (2.1%-4.6%) in the community versus 5.6% (5.1%-9.5%) and 2.8% (2.2%-5.0%) in 2019). The largest changes in future prevalence were observed in simulations that assumed changes in overall antimicrobial consumption. When overall antimicrobial consumption was set to decrease by 50%, prevalence in 2025 declined by 89% in hospitals and by 84% in the community. A 50% decline in transmission rate within hospitals led to a reduction in prevalence of 43% in hospitals and of 13% in the community by 2025. Prevalence changed much less (≤9%) across scenarios with reduced carbapenem consumption. Assuming higher rates for the contribution from external sources of colonization, led to decreasing estimations of future prevalence in hospitals. While high uncertainty remains on the magnitude of these contribution, the best model fit suggested that as much as 46% (95% CI: 12%-96 %) of observed colonizations could be attributable to sources other than human-to-human transmission within the geographical setting (i.e., non-local transmission).
Conclusions This study suggests that overall antimicrobial consumption will be, by far, the most powerful driver of future prevalence and that a large fraction of colonizations could be attributed to non-local transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by an institutional grant (CTU Forschungsgrant der Inselgruppe)
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Available upon request: http://www.anresis.ch/
